Lupin Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Excellent return on equity (ROE 28.7%)
- Efficient capital deployment (ROCE 29.9%)
- Attractively valued vs sector (P/E 14.8x vs industry 50.2x)
- Low debt relative to equity (D/E 0.3x)
- Near 52-week low — potential value zone (₹1,893)
Concerns
Today's Price Action
The stock closed at ₹1,972.7, matching the previous close and showing a flat intraday movement.成交量 recorded 3,70,792 shares, exactly equal to the 20‑day average, indicating that trading activity is typical for the security and there is no immediate pressure from either buyers or sellers.
Valuation Snapshot
The trailing PE ratio stands at 14.8, a figure that cannot be benchmarked against a sector‑wide PE because the healthcare index reports a sector PE of zero. A price‑to‑book multiple of 0.9 together with a robust return on equity of 28.7 % underscores strong profitability relative to the book value of assets.
Key Levels to Watch
The current price sits just above the 52‑week low of ₹1,893, leaving a modest upside cushion before the lower end of the yearly range is breached. Open‑interest data for the nearest monthly options series shows a concentration of contracts around the ₹2,050 strike, which could act as a short‑term magnet for price movement.
Chart Pattern
On the daily chart a hammer candlestick formed six trading sessions ago, a bullish‑type reversal pattern that suggests a prior downtrend may have exhausted its momentum. The pattern appeared on the 1‑day timeframe and reflects a relatively long lower shadow with a small real body at the high end of the range.
Data Summary
Key metrics for the company include a PE of 14.8, a PB of 0.9 and an ROE of 28.7 %, while the market capitalisation is recorded at ₹0 Cr. The stock’s 52‑week range is ₹1,893–₹2,530, and volume today aligns exactly with its 20‑day average of 3,70,792 shares.
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
LUPIN · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 47.04% | 47.01% | 46.99% | 46.96% | 46.94% | 46.91% |
| FII | 16.11% | 18.29% | 19.32% | 21.50% | 22.04% | 21.46% |
| DII | 29.72% | 27.76% | 26.77% | 25.10% | 24.73% | 25.41% |
| Public | 7.10% | 6.93% | 6.92% | 6.44% | 6.27% | 6.21% |
| Govt | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
Corporate Events
To consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026.
To consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.
Dividend - Rs 18 Per Share
To consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026, and recommend dividend, if any.
Dividend - Rs 12 Per Share
Dividend - Rs 8 Per Share
Dividend - Rs 4 Per Share
Latest News
All newsZydus, Lupin face FDA flag on weight-loss injectable exports
*Zydus, Lupin face FDA flag on weight-loss injectable exports* — The U.S. FDA issued a warning letter over quality issues in weight-loss injectables exported by Indian firms Zydus and Lupin. This may disrupt shipments and trigger regulatory scrutiny. Shares may face near-term pressure as compliance costs or plant upgrades loom. **No patient harm reported**, but export delays could impact revenue. 📊 *STOCKS:* ZYDUSLIFE, LUPIN | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #FDA
Lupin gets USFDA nod for generic Lokelma
*Lupin gets USFDA nod for generic Lokelma* clears path to enter the **$568M** US hyperkalemia market. The approval allows Lupin to launch a generic version of Lokelma, boosting revenue potential. This positions Lupin competitively in the cardiovascular-renal space. 📊 *STOCKS:* $LUPIN | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Approval
Lupin appoints Brian Savage as President and Chief Legal Officer
*Lupin appoints Brian Savage as President and Chief Legal Officer* — Lupin has announced the appointment of Brian Savage in a key leadership role. This move strengthens the company’s legal and corporate governance framework. The change reflects strategic reinforcement ahead of future growth initiatives. 📊 *STOCKS:* $LUPIN | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #LeadershipChange
Lupin launches world's first COPD triple-combo drug Formoflo-G® MDI
*Lupin launches world's first COPD triple-combo drug Formoflo-G® MDI*. Lupin has launched Formoflo-G® MDI, the world’s first fixed-dose triple combination inhaler for COPD management. The product combines **three active ingredients** in a single dose, targeting improved patient compliance and efficacy. This launch strengthens Lupin’s respiratory portfolio in chronic lung diseases. 📊 *STOCKS:* $LUPIN | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma
Lupin's subsidiary becomes fully owned after share buyback
*Lupin's subsidiary becomes fully owned after share buyback* — Lupin Limited announced that Multicare Pharmaceuticals Philippines, Inc. (MPPI) completed a buyback of **30,559 shares**, making it a step-down wholly owned subsidiary effective October 1, 2026. This move strengthens Lupin’s control over its international operations. The development reflects strategic consolidation within its global structure. 📊 *STOCKS:* $LUPIN | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma
Lupin gets FDA tentative approval for Apixaban oral suspension
*Lupin gets FDA tentative approval for Apixaban oral suspension*. Lupin Limited has received tentative approval from the U.S. FDA for its Apixaban Oral Suspension, **20 mg/5 mL**, a generic version of Eliquis Oral Suspension. The product is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Tentative approval means the drug can be marketed upon fulfillment of certain conditions, including final FDA clearance and patent expiry. 📊 *STOCKS:* $LUPIN | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #FDA
Lupin gets U.S. FDA approval for Sugammadex Injection.
*Lupin gets U.S. FDA approval for Sugammadex Injection.* The company has launched the generic version of the drug in the U.S. market, which is used during anesthesia. This approval expands Lupin’s presence in the U.S. specialty generics segment. The product has **$XX million** in annual sales, offering near-term revenue potential. 📊 *STOCKS:* $LUPIN | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #FDA
Lupin partners with ERN to launch Luforbec® in Spain
*Lupin partners with ERN to launch Luforbec® in Spain*. Lupin Limited has announced a collaboration with ERN to launch Luforbec® (beclometasone/formoterol) pMDI in Spain. The product is indicated for asthma and COPD management. This marks Lupin’s strategic expansion into the European respiratory market. 📊 *STOCKS:* LUPIN | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma
Lupin completes buyback, MPPI becomes subsidiary
*Lupin completes buyback, MPPI becomes subsidiary.* The company’s buyback of shares in MPPI has concluded, resulting in MPPI becoming a wholly-owned subsidiary. This strategic move strengthens Lupin’s control over its international operations. The transaction underscores Lupin’s commitment to optimizing its global structure. 📊 *STOCKS:* $LUPIN | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Buyback
Lupin receives ESG rating from Crisil
*Lupin receives ESG rating from Crisil* Lupin Limited has been assigned an ESG rating by Crisil ESG Ratings and Analytics Ltd. The rating reflects the company's environmental, social, and governance practices. While **no financial figures** were disclosed, the assessment may influence investor sentiment over time. This is part of ongoing corporate disclosures. 📊 *STOCKS:* $LUPIN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ESG
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹7.2K Cr 1.7% | ₹7.0K Cr 12.4% | ₹6.3K Cr 10.6% | ₹5.7K Cr 1.8% | ₹5.8K Cr 1.7% | ₹5.7K Cr 1.3% | ₹5.6K Cr 12.9% | ₹5.0K Cr |
| Op. Profit | ₹2.3K Cr 3.4% | ₹2.3K Cr 35.6% | ₹1.7K Cr 30.7% | ₹1.3K Cr 2.6% | ₹1.4K Cr 1.2% | ₹1.3K Cr 8.0% | ₹1.2K Cr 24.5% | ₹997 Cr |
| OPM | 32.0% 3.0% | 33.0% 17.9% | 28.0% 21.7% | 23.0% 4.2% | 24.0% 0.0% | 24.0% 9.1% | 22.0% 10.0% | 20.0% |
| Net Profit | ₹1.2K Cr 20.5% | ₹1.5K Cr 21.6% | ₹1.2K Cr 56.1% | ₹782 Cr 9.0% | ₹859 Cr 0.0% | ₹859 Cr 6.6% | ₹806 Cr 119.0% | ₹368 Cr |
| EPS (₹) | 25.73 20.5% | 32.36 21.2% | 26.69 57.7% | 16.92 9.7% | 18.74 0.3% | 18.69 6.3% | 17.58 122.8% | 7.89 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹28.0K Cr 23.1% | ₹22.7K Cr 13.5% | ₹20.0K Cr 20.2% | ₹16.6K Cr 1.4% | ₹16.4K Cr 8.2% | ₹15.2K Cr 1.4% | ₹15.4K Cr 4.8% | ₹14.7K Cr 7.2% | ₹15.8K Cr 9.0% | ₹17.4K Cr |
| Expenses | ₹19.8K Cr 13.6% | ₹17.4K Cr 7.5% | ₹16.2K Cr 8.6% | ₹14.9K Cr 7.8% | ₹16.2K Cr 28.5% | ₹12.6K Cr 3.3% | ₹13.0K Cr 7.6% | ₹12.1K Cr 4.3% | ₹12.6K Cr 1.7% | ₹12.9K Cr |
| Op. Profit | ₹8.2K Cr 54.6% | ₹5.3K Cr 38.9% | ₹3.8K Cr 120.8% | ₹1.7K Cr 685.8% | ₹219 Cr 91.5% | ₹2.6K Cr 9.0% | ₹2.4K Cr 8.0% | ₹2.6K Cr 18.6% | ₹3.1K Cr 30.1% | ₹4.5K Cr |
| OPM | 29.0% 26.1% | 23.0% 21.1% | 19.0% 90.0% | 10.0% 669.2% | 1.3% 92.4% | 17.0% 13.3% | 15.0% 11.8% | 17.0% 15.0% | 20.0% 23.1% | 26.0% |
| Other Income | ₹523 Cr 158.9% | ₹202 Cr 54.2% | ₹131 Cr 13.2% | ₹151 Cr 28.1% | ₹210 Cr 52.2% | ₹138 Cr 203.0% | ₹-134 Cr 247.3% | ₹91 Cr 106.9% | ₹-1.3K Cr 1335.8% | ₹106 Cr |
| Interest | ₹434 Cr 47.1% | ₹295 Cr 5.4% | ₹312 Cr 13.9% | ₹274 Cr 91.6% | ₹143 Cr 1.4% | ₹141 Cr 61.2% | ₹363 Cr 20.2% | ₹302 Cr 48.0% | ₹204 Cr 33.3% | ₹153 Cr |
| Depreciation | ₹1.4K Cr 17.7% | ₹1.2K Cr 2.3% | ₹1.2K Cr 35.9% | ₹881 Cr 46.9% | ₹1.7K Cr 87.0% | ₹887 Cr 8.6% | ₹970 Cr 14.7% | ₹846 Cr 22.1% | ₹1.1K Cr 19.1% | ₹912 Cr |
| PBT | ₹6.9K Cr 71.2% | ₹4.0K Cr 65.8% | ₹2.4K Cr 238.3% | ₹716 Cr 152.2% | ₹-1.4K Cr 181.9% | ₹1.7K Cr 89.0% | ₹887 Cr 41.0% | ₹1.5K Cr 174.8% | ₹547 Cr 84.6% | ₹3.5K Cr |
| Tax % | 22.0% 22.2% | 18.0% 10.0% | 20.0% 47.4% | 38.0% 280.0% | 10.0% 63.0% | 27.0% 79.2% | 130.0% 120.3% | 59.0% 11.3% | 53.0% 89.3% | 28.0% |
| Net Profit | ₹5.4K Cr 62.0% | ₹3.3K Cr 70.8% | ₹1.9K Cr 332.1% | ₹448 Cr 129.3% | ₹-1.5K Cr 224.4% | ₹1.2K Cr 554.8% | ₹-270 Cr 143.9% | ₹615 Cr 138.4% | ₹258 Cr 89.9% | ₹2.6K Cr |
| EPS (₹) | 116.65 62.3% | 71.88 71.1% | 42.01 344.6% | 9.45 128.1% | -33.62 225.4% | 26.81 550.6% | -5.95 144.4% | 13.4 141.0% | 5.56 90.2% | 56.63 |
| Div Payout | 15.0% 11.8% | 17.0% 10.5% | 19.0% 54.8% | 42.0% 450.0% | -12.0% 150.0% | 24.0% 123.8% | -101.0% 373.0% | 37.0% 58.9% | 90.0% 592.3% | 13.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹91 Cr 0.0% | ₹91 Cr 0.0% | ₹91 Cr 0.0% | ₹91 Cr 0.0% | ₹91 Cr 0.0% | ₹91 Cr 0.0% | ₹91 Cr 1.1% | ₹90 Cr 0.0% | ₹90 Cr 0.0% | ₹90 Cr |
| Reserves | ₹19.5K Cr 14.2% | ₹17.1K Cr 20.5% | ₹14.2K Cr 14.7% | ₹12.4K Cr 2.6% | ₹12.1K Cr 12.0% | ₹13.7K Cr 10.2% | ₹12.4K Cr 8.8% | ₹13.7K Cr 1.2% | ₹13.5K Cr 0.6% | ₹13.4K Cr |
| Borrowings | ₹6.2K Cr 14.1% | ₹5.4K Cr 86.4% | ₹2.9K Cr 35.7% | ₹4.5K Cr 9.2% | ₹4.2K Cr 13.1% | ₹4.8K Cr 24.1% | ₹6.3K Cr 25.8% | ₹8.5K Cr 18.9% | ₹7.1K Cr 10.3% | ₹8.0K Cr |
| Other Liabilities | ₹7.7K Cr 20.9% | ₹6.3K Cr 3.2% | ₹6.5K Cr 12.9% | ₹5.8K Cr 8.5% | ₹5.3K Cr 10.2% | ₹4.8K Cr 18.8% | ₹6.0K Cr 10.0% | ₹5.4K Cr 2.3% | ₹5.3K Cr 11.6% | ₹4.7K Cr |
| Total Liabilities | ₹33.5K Cr 15.6% | ₹29.0K Cr 22.0% | ₹23.8K Cr 4.2% | ₹22.8K Cr 5.3% | ₹21.7K Cr 7.6% | ₹23.4K Cr 5.6% | ₹24.8K Cr 10.3% | ₹27.7K Cr 6.3% | ₹26.0K Cr 0.7% | ₹26.2K Cr |
Assets | ||||||||||
| Fixed Assets | ₹10.3K Cr 5.5% | ₹9.7K Cr 9.5% | ₹8.9K Cr 6.3% | ₹8.4K Cr 13.2% | ₹7.4K Cr 6.3% | ₹7.9K Cr 0.7% | ₹7.9K Cr 28.4% | ₹11.1K Cr 7.0% | ₹10.4K Cr 6.1% | ₹11.0K Cr |
| CWIP | ₹593 Cr 14.7% | ₹517 Cr 33.1% | ₹773 Cr 37.6% | ₹1.2K Cr 8.0% | ₹1.1K Cr 7.5% | ₹1.1K Cr 13.4% | ₹940 Cr 42.7% | ₹1.6K Cr 36.9% | ₹2.6K Cr 21.8% | ₹2.1K Cr |
| Investments | ₹3.3K Cr 190.7% | ₹1.1K Cr 6.6% | ₹1.1K Cr 107.9% | ₹517 Cr 42.6% | ₹900 Cr 63.3% | ₹2.5K Cr 3.4% | ₹2.4K Cr 3.4% | ₹2.3K Cr 776.0% | ₹262 Cr 87.7% | ₹2.1K Cr |
| Other Assets | ₹19.3K Cr 9.8% | ₹17.6K Cr 35.1% | ₹13.0K Cr 2.6% | ₹12.7K Cr 3.8% | ₹12.2K Cr 1.6% | ₹12.0K Cr 11.3% | ₹13.6K Cr 7.3% | ₹12.6K Cr 1.2% | ₹12.8K Cr 17.3% | ₹10.9K Cr |
| Total Assets | ₹33.5K Cr 15.6% | ₹29.0K Cr 22.0% | ₹23.8K Cr 4.2% | ₹22.8K Cr 5.3% | ₹21.7K Cr 7.6% | ₹23.4K Cr 5.6% | ₹24.8K Cr 10.3% | ₹27.7K Cr 6.3% | ₹26.0K Cr 0.7% | ₹26.2K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹3.0K Cr 17.8% | ₹3.6K Cr 92.3% | ₹1.9K Cr 416.9% | ₹367 Cr 79.9% | ₹1.8K Cr 24.0% | ₹1.5K Cr 11.8% | ₹1.7K Cr 4.9% | ₹1.8K Cr 57.4% | ₹4.1K Cr 1177.0% | ₹-382 Cr |
| Investing CF | ₹-4.2K Cr 143.7% | ₹-1.7K Cr 33.0% | ₹-1.3K Cr 199.6% | ₹1.3K Cr 204.2% | ₹-1.2K Cr 212.0% | ₹1.1K Cr 133.7% | ₹-3.3K Cr 798.3% | ₹470 Cr 118.6% | ₹-2.5K Cr 62.7% | ₹-6.8K Cr |
| Financing CF | ₹1.7K Cr 179.3% | ₹-2.2K Cr 548.1% | ₹-337 Cr 78.6% | ₹-1.6K Cr 16.6% | ₹-1.9K Cr 111.6% | ₹-891 Cr 219.8% | ₹744 Cr 149.9% | ₹-1.5K Cr 444.6% | ₹433 Cr 92.6% | ₹5.8K Cr |
| Net Cash Flow | ₹560 Cr 325.8% | ₹-248 Cr 190.8% | ₹273 Cr 213.8% | ₹87 Cr 106.7% | ₹-1.3K Cr 177.3% | ₹1.7K Cr 293.2% | ₹-872 Cr 219.6% | ₹729 Cr 63.9% | ₹2.0K Cr 253.5% | ₹-1.3K Cr |
| Free Cash Flow | ₹1.3K Cr 50.7% | ₹2.7K Cr 526.6% | ₹436 Cr 182.1% | ₹-531 Cr 146.2% | ₹1.1K Cr 44.1% | ₹798 Cr 13.0% | ₹706 Cr 170.5% | ₹261 Cr 82.7% | ₹1.5K Cr 124.5% | ₹-6.2K Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 88d 2.3% | 86d 12.2% | 98d 3.2% | 95d 12.0% | 108d 16.3% | 129d 0.8% | 128d 6.7% | 120d 31.9% | 91d 21.6% | 116d |
| Inventory Days | 292d 7.4% | 272d 12.4% | 242d 7.3% | 261d 6.5% | 279d 20.3% | 232d 18.0% | 283d 11.9% | 253d 4.9% | 266d 3.6% | 276d |
| Days Payable | 158d 3.1% | 163d 19.9% | 136d 5.4% | 129d 5.8% | 137d 15.4% | 162d 12.0% | 184d 3.4% | 178d 5.8% | 189d 12.5% | 168d |
| Cash Conv. Cycle | 223d 14.4% | 195d 4.4% | 204d 10.1% | 227d 8.8% | 249d 25.1% | 199d 12.3% | 227d 16.4% | 195d 16.8% | 167d 25.8% | 225d |
| Working Capital Days | 58d 9.4% | 53d 65.6% | 32d 28.9% | 45d 32.4% | 34d 3.0% | 33d 71.3% | 115d 8.7% | 126d 100.0% | 63d 38.2% | 102d |
| ROCE | 21.0% 31.3% | 16.0% 166.7% | 6.0% 185.7% | -7.0% 177.8% | 9.0% 0.0% | 9.0% 10.0% | 10.0% 0.0% | 10.0% 47.4% | 19.0% 20.8% | 24.0% |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Lupin Limited
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
HealthcarePharmaceuticals & Biotechnology